[go: up one dir, main page]

ECSP17014972A - Compuestos de azetidiniloxifenilpirrolidina - Google Patents

Compuestos de azetidiniloxifenilpirrolidina

Info

Publication number
ECSP17014972A
ECSP17014972A ECIEPI201714972A ECPI201714972A ECSP17014972A EC SP17014972 A ECSP17014972 A EC SP17014972A EC IEPI201714972 A ECIEPI201714972 A EC IEPI201714972A EC PI201714972 A ECPI201714972 A EC PI201714972A EC SP17014972 A ECSP17014972 A EC SP17014972A
Authority
EC
Ecuador
Prior art keywords
azetidinyloxphenylpyrrolidine
compounds
please see
see attached
attached
Prior art date
Application number
ECIEPI201714972A
Other languages
English (en)
Inventor
Joshua O Odingo
Roberto E F Lli C S A S Graziani
Danwen Huang
Gary G Deng
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54140711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP17014972(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP17014972A publication Critical patent/ECSP17014972A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Favor ver adjunto
ECIEPI201714972A 2014-09-12 2017-03-14 Compuestos de azetidiniloxifenilpirrolidina ECSP17014972A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462049485P 2014-09-12 2014-09-12

Publications (1)

Publication Number Publication Date
ECSP17014972A true ECSP17014972A (es) 2018-03-31

Family

ID=54140711

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201714972A ECSP17014972A (es) 2014-09-12 2017-03-14 Compuestos de azetidiniloxifenilpirrolidina

Country Status (34)

Country Link
US (2) US10781202B2 (es)
EP (1) EP3191466B1 (es)
JP (1) JP6285610B2 (es)
KR (1) KR101857931B1 (es)
CN (1) CN106795137B (es)
AP (1) AP2017009778A0 (es)
AR (1) AR101696A1 (es)
AU (1) AU2015315533B2 (es)
BR (1) BR112017002852A2 (es)
CA (1) CA2955634A1 (es)
CL (1) CL2017000484A1 (es)
CO (1) CO2017001389A2 (es)
CR (1) CR20170050A (es)
DK (1) DK3191466T3 (es)
EA (1) EA030034B1 (es)
EC (1) ECSP17014972A (es)
ES (1) ES2770047T3 (es)
HR (1) HRP20200119T1 (es)
HU (1) HUE047551T2 (es)
IL (1) IL250378A0 (es)
LT (1) LT3191466T (es)
MX (1) MX2017003138A (es)
NZ (1) NZ729087A (es)
PE (1) PE20170328A1 (es)
PH (1) PH12017500459A1 (es)
PL (1) PL3191466T3 (es)
PT (1) PT3191466T (es)
RS (1) RS59845B1 (es)
SG (1) SG11201701225YA (es)
SI (1) SI3191466T1 (es)
TN (1) TN2017000047A1 (es)
TW (1) TW201625591A (es)
WO (1) WO2016040083A1 (es)
ZA (1) ZA201700555B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014230814B2 (en) 2013-03-14 2017-12-21 Boehringer Ingelheim International Gmbh Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C
AP2017009733A0 (en) 2014-09-12 2017-02-28 Boehringer Ingelheim Int Spirocyclic inhibitors of cathepsin c
CA3123995C (en) * 2018-12-18 2023-05-23 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company Phenylpyrrolidine compound and use thereof
CN111333625B (zh) * 2018-12-18 2022-10-18 武汉人福创新药物研发中心有限公司 苯基吡咯烷类化合物及其用途
CN111333637B (zh) * 2018-12-18 2022-07-29 武汉人福创新药物研发中心有限公司 苯基吡咯烷类衍生物及其制备方法
WO2021036953A1 (zh) * 2019-08-23 2021-03-04 湖北生物医药产业技术研究院有限公司 苯基吡咯烷类化合物
US20240217974A1 (en) 2021-04-29 2024-07-04 Suzhou Suncadia Biopharmaceuticals Co., Ltd. Isoquinolone compound and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258833B1 (en) * 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
CA2436551A1 (en) * 2001-01-31 2002-08-08 Pfizer Products Inc. Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
RU2435588C2 (ru) 2005-09-29 2011-12-10 Байер Шеринг Фарма Акциенгезельшафт Ингибиторы фдэ и их комбинации для лечения урологических расстройств
TW201206440A (en) 2010-04-28 2012-02-16 Astellas Pharma Inc Prophylactic or therapeutic agent for diseases associated with pains in urinary organs
JO3264B1 (ar) * 2013-03-13 2018-09-16 Lilly Co Eli مركبات ازيتيدينيل أوكسي فينيل بيروليدين
WO2016033776A1 (en) * 2014-09-04 2016-03-10 Eli Lilly And Company Crystalline (2s) -3- [ (3s, 4s) -3- [ (1r) -1-hydroxyethyl] -4- (4-methoxy-3- { [1- (5-methylpyridin-2-yl) azetidin-3-yl] oxy} phenyl) -3-methylpyrrolidin-1-yl] -3-oxopropane-1, 2-diol

Also Published As

Publication number Publication date
PL3191466T3 (pl) 2020-05-18
CN106795137B (zh) 2020-08-25
AP2017009778A0 (en) 2017-03-31
CO2017001389A2 (es) 2017-05-10
AR101696A1 (es) 2017-01-04
WO2016040083A1 (en) 2016-03-17
PE20170328A1 (es) 2017-04-19
IL250378A0 (en) 2017-03-30
CR20170050A (es) 2017-04-25
AU2015315533A1 (en) 2017-02-23
LT3191466T (lt) 2020-02-25
EP3191466A1 (en) 2017-07-19
HUE047551T2 (hu) 2020-04-28
BR112017002852A2 (pt) 2017-12-26
EA030034B1 (ru) 2018-06-29
NZ729087A (en) 2018-07-27
HRP20200119T1 (hr) 2020-04-03
PH12017500459A1 (en) 2017-07-31
SI3191466T1 (sl) 2020-02-28
US20200002318A1 (en) 2020-01-02
CN106795137A (zh) 2017-05-31
TN2017000047A1 (en) 2018-07-04
RS59845B1 (sr) 2020-02-28
CA2955634A1 (en) 2016-03-17
KR20170040803A (ko) 2017-04-13
US10781202B2 (en) 2020-09-22
DK3191466T3 (da) 2020-01-20
ZA201700555B (en) 2018-12-19
US20170240532A1 (en) 2017-08-24
JP6285610B2 (ja) 2018-02-28
EP3191466B1 (en) 2019-12-04
JP2017527587A (ja) 2017-09-21
ES2770047T3 (es) 2020-06-30
PT3191466T (pt) 2020-02-17
CL2017000484A1 (es) 2017-11-10
MX2017003138A (es) 2017-05-23
KR101857931B1 (ko) 2018-05-14
EA201790156A1 (ru) 2017-06-30
TW201625591A (zh) 2016-07-16
SG11201701225YA (en) 2017-03-30
AU2015315533B2 (en) 2018-03-15

Similar Documents

Publication Publication Date Title
NL301227I2 (nl) Tabelecleucel
ECSP17029371A (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
GEAP202114450A (en) Anti-tigit antibodies
ECSP17015977A (es) Terapia de combinacion
GEAP201814347A (en) Substituted dihydroisoquinoline compounds
DK3174666T3 (da) Dynamisk dirigeret emnepositioneringssystem
DK3135079T3 (da) Zonebaseret belysningsadgang
IN2015DE00625A (es)
ECSP17014972A (es) Compuestos de azetidiniloxifenilpirrolidina
BR112016030730A2 (pt) Composto
CL2016002165A1 (es) Compuestos de aminocarbonilcarbamato
MA40836A (fr) Procédures de semi-synthèse
ECSP17050310A (es) Ciclopropabenzofuranil-piridopirazindionas novedosas
DE112015002984A5 (de) Positioniereinheit
DE112015002149A5 (de) Beleuchtungseinrichtung
DE102015015061A8 (de) Beleuchtungsvorrichtung
DE112015001852A5 (de) Gehäuseanordnung
GB201410669D0 (en) Light source
GEAP201814327A (en) Treatment regimen tiacumicin compound
DE112014006602A5 (de) Positioniersystem
GT201400039S (es) Diseño de bici-motocicleta
TN2014000388A1 (fr) منظومة فيزيائية متجانسة كهربائية ميكانيكية مغناطيسية لتوليد الطاقة الكهربائية الحرة الايكولوجية المضاعفة
TN2014000354A1 (fr) جهاز مبتكر لتلقيح النخيل
GT201400038S (es) Diseño de motocicleta
GT201400037S (es) Diseño de motocicleta